Anorexiants Market Size, Share & Trends Report

Anorexiants Market (2024 - 2030) Size, Share & Trends Analysis Report By Route Of Administration (Subcutaneous Anorexiants, Oral Anorexiants), By Distribution Channel, By Region, And Segment Forecasts

Market Segmentation

Treatment Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- GLP-1 Receptor Agonists
  - Semaglutide (Wegovy)
  - Liraglutide (Saxenda)
  - Tirzepatide (Zepbound)
- Lipase Inhibitors
- Appetite Suppressants
- Other Drug Class
Treatment Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Parenteral
- Oral
Treatment Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- Others
Treatment Market Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Obesity Treatment Market, Drug Class
    - GLP-1 Receptor Agonists
      - Semaglutide (Wegovy)
      - Liraglutide (Saxenda)
      - Tirzepatide (Zepbound)
    - Lipase Inhibitors
    - Appetite Suppressants
    - Other Drug Class
  - North America Obesity Treatment Market, Route of Administration
    - Parenteral
    - Oral
  - North America Obesity Treatment Market, Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Others
  - U.S.
    - U.S. Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - U.S. Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - U.S. Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Canada
    - Canada Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Canada Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Canada Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Mexico
    - Mexico Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Mexico Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Mexico Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
- Europe
  - Europe Obesity Treatment Market, Drug Class
    - GLP-1 Receptor Agonists
      - Semaglutide (Wegovy)
      - Liraglutide (Saxenda)
      - Tirzepatide (Zepbound)
    - Lipase Inhibitors
    - Appetite Suppressants
    - Other Drug Class
  - Europe Obesity Treatment Market, Route of Administration
    - Parenteral
    - Oral
    - Others
  - Europe Obesity Treatment Market, Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Others
  - U.K.
    - U.K. Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - U.K. Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - U.K. Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Germany
    - Germany Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Germany Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Germany Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - France
    - France Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - France Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - France Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Italy
    - Italy Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Italy Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Italy Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Spain
    - Spain Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Spain Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Spain Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
    - Denmark
      - Denmark Obesity Treatment Market, Drug Class
        
        GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
        
        Lipase Inhibitors
        
        Appetite Suppressants
        
        Other Drug Class
      - Denmark Obesity Treatment Market, Route of Administration
        
        Parenteral
        
        Oral
        
        Others
      - Denmark Obesity Treatment Market, Distribution Channel
        
        Hospital Pharmacies
        
        Retail Pharmacies
        
        Others
  - Sweden
    - Sweden Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors Appetite Suppressants
      - Other Drug Class
    - Sweden Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Sweden Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Norway
    - Norway Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Norway Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Norway Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
- Asia Pacific
  - Asia Pacific Obesity Treatment Market, Drug Class
    - GLP-1 Receptor Agonists
      - Semaglutide (Wegovy)
      - Liraglutide (Saxenda)
      - Tirzepatide (Zepbound)
    - Lipase Inhibitors
    - Appetite Suppressants
    - Other Drug Class
  - Asia Pacific Obesity Treatment Market, Route of Administration
    - Parenteral
    - Oral
    - Others
  - Asia Pacific Obesity Treatment Market, Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Others
  - China
    - China Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - China Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - China Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Japan
    - Japan Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Japan Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Japan Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - India
    - India Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - India Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - India Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Australia
    - Australia Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Australia Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Australia Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - South Korea
    - South Korea Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - South Korea Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - South Korea Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Thailand
    - Thailand Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Thailand Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Thailand Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
- Latin America
  - Latin America Obesity Treatment Market, Drug Class
    - GLP-1 Receptor Agonists
      - Semaglutide (Wegovy)
      - Liraglutide (Saxenda)
      - Tirzepatide (Zepbound)
    - Lipase Inhibitors
    - Appetite Suppressants
    - Other Drug Class
  - Latin America Obesity Treatment Market, Route of Administration
    - Parenteral
    - Oral
    - Others
  - Latin America Obesity Treatment Market, Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Others
  - Brazil
    - Brazil Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Brazil Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Brazil Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Argentina
    - Argentina Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Argentina Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Argentina Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
- Middle East & Africa
  - Middle East & Africa Obesity Treatment Market, Drug Class
    - GLP-1 Receptor Agonists
      - Semaglutide (Wegovy)
      - Liraglutide (Saxenda)
      - Tirzepatide (Zepbound)
    - Lipase Inhibitors
    - Appetite Suppressants
    - Other Drug Class
  - Middle East & Africa Obesity Treatment Market, Route of Administration
    - Parenteral
    - Oral
    - Others
  - Middle East & Africa Obesity Treatment Market, Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Others
  - South Africa
    - South Africa Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - South Africa Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - South Africa Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Saudi Arabia
    - Saudi Arabia Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Saudi Arabia Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Saudi Arabia Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - UAE
    - UAE Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - UAE Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - UAE Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others
  - Kuwait
    - Kuwait Obesity Treatment Market, Drug Class
      - GLP-1 Receptor Agonists
        
        Semaglutide (Wegovy)
        
        Liraglutide (Saxenda)
        
        Tirzepatide (Zepbound)
      - Lipase Inhibitors
      - Appetite Suppressants
      - Other Drug Class
    - Kuwait Obesity Treatment Market, Route of Administration
      - Parenteral
      - Oral
      - Others
    - Kuwait Obesity Treatment Market, Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments